INDV vs RBBN vs AVPT vs BHVN vs ALKS

For growth investors, AvePoint, Inc.

(AVPT) is the stronger pick with 26. 9% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Ribbon Communications Inc. (RBBN) offers the better valuation at 12. 2x trailing P/E (20. 7x forward), making it the more compelling value choice. Analysts rate Indivior Pharmaceuticals Inc (INDV) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Ribbon Communications Inc.

(RBBN) is the cheapest at 12. 2x versus AvePoint, Inc. at 68. 8x. On forward P/E, Indivior Pharmaceuticals Inc is actually cheaper at 12. 7x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Indivior Pharmaceuticals Inc (INDV) delivered a total return of +268.

4%, compared to -61. 0% for Ribbon Communications Inc. (RBBN). Over 10 years, the gap is even starker: INDV returned +281. 7% versus RBBN's -68. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Indivior Pharmaceuticals Inc (INDV) is the lower-risk stock at 0.

68β versus Ribbon Communications Inc. 's 1. 49β — meaning RBBN is approximately 120% more volatile than INDV relative to the S&P 500. On balance sheet safety, AvePoint, Inc. (AVPT) carries a lower debt/equity ratio of 2% versus 5% for Biohaven Ltd. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AvePoint, Inc.

(AVPT) is pulling ahead at 26. 9% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Indivior Pharmaceuticals Inc grew EPS 108. 3% year-over-year, compared to -34. 1% for Alkermes plc. Over a 3-year CAGR, AVPT leads at 21. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Indivior Pharmaceuticals Inc (INDV) is the more profitable company, earning 16.

9% net margin versus 0. 0% for Biohaven Ltd. — meaning it keeps 16. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INDV leads at 21. 4% versus 0. 0% for BHVN. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Indivior Pharmaceuticals Inc (INDV) trades at 12.

7x forward P/E versus 27. 7x for AvePoint, Inc. — 15. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BHVN: 118. 7% to $21. 29.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Indivior Pharmaceuticals Inc (INDV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

68), +281. 7% 10Y return). Both have compounded well over 10 years (INDV: +281. 7%, RBBN: -68. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (INDV (Healthcare) and RBBN (Communication Services) and AVPT (Technology) and BHVN (Healthcare) and ALKS (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: INDV is a small-cap quality compounder stock; RBBN is a small-cap deep-value stock; AVPT is a small-cap high-growth stock; BHVN is a small-cap quality compounder stock; ALKS is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.